Finance

Beta
Lists
PVLA:NASDAQ
Palvella Therapeutics Inc
$143.94
+15.94%
(+19.79) 1D
$141.00
-2.04% (-2.94)
After hours
Closed: Jul 21, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PVLA...
Open
$123.84
High
$145.98
Low
$120.61
Mkt. cap
2.06B
Avg. vol.
318.62K
Volume
364.77K
52-wk high
$161.38
52-wk low
$31.01
EPS
-$4.16
Beta
-0.20
Shares outstanding
14.34M
No. of employees
29
Open
$123.84
High
$145.98
Low
$120.61
Mkt. cap
2.06B
Avg. vol.
318.62K
Volume
364.77K
52-wk high
$161.38
52-wk low
$31.01
EPS
-$4.16
Beta
-0.20
Shares outstanding
14.34M
No. of employees
29
News stories
From sources across the web
About Palvella Therapeutics Inc
CEO-
Employees29
Founded-
Headquarters-
SectorBiotechnology
Websitepalvellatx.com
Analyst ratings
Based on 12 analysts giving stock ratings to PVLA in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for PVLA in the last 3 months.
Highest
Current $143.94
$270.00 (+87.58%)
Average
$233.55 (+62.26%)
Lowest
$205.00 (+42.42%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sam Slutsky
LifeSci Capital
Buy
Maintained
$225.00
+56.3%
07/20/2026
Ritu Baral
TD Cowen
Buy
Reiterated
$267.00
+85.5%
07/21/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$215.00
+49.4%
07/20/2026
Whitney Ijem
Canaccord Genuity
Buy
Reiterated
$227.00
+57.7%
07/20/2026
Trevor Allred
Oppenheimer
Buy
Reiterated
$210.00
+45.9%
07/21/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
$240.00
+66.7%
07/01/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$250.00
+73.7%
06/24/2026
Albert Lowe
Craig-Hallum
Buy
Reiterated
$205.00
+42.4%
06/22/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$270.00
+87.6%
06/11/2026
Danielle Brill
Truist Financial
Buy
Maintained
-
-
05/21/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$240.00
+66.7%
05/20/2026
Sudan Loganathan
Stephens
Buy
Initiated
$220.00
+52.8%
05/11/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$220.00
+52.8%
03/02/2026
Catherine Novack
JonesTrading
Buy
Maintained
$209.00
+45.2%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
5.12M
6.53M
7.12M
9.33M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.13M
3.65M
4.18M
5.52M
Operating expense
9.25M
10.18M
11.30M
14.86M
Total operating expenses
9.25M
10.18M
11.30M
14.86M
Operating income
-9.25M
-10.18M
-11.30M
-14.86M
Other non operating income
443.00K
-286.00K
-191.00K
54.00K
EBT including unusual items
-9.47M
-11.34M
-12.71M
-15.77M
EBT excluding unusual items
-9.47M
-11.34M
-12.71M
-15.77M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-9.47M
-11.34M
-12.71M
-15.77M
Net profit margin
-
-
-
-
Earnings per share
-0.86
-1.03
-1.08
-1.20
Interest and investment income
690.00K
628.00K
520.00K
1.07M
Interest expense
-1.35M
-1.51M
-1.74M
-2.04M
Net interest expenses
-664.00K
-882.00K
-1.22M
-966.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer